BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 20526231)

  • 1. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy.
    Lim JW; Kim MU; Shin MC
    Retina; 2010 Oct; 30(9):1465-71. PubMed ID: 20526231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy.
    Shin MC; Lim JW
    Retina; 2011 Oct; 31(9):1937-43. PubMed ID: 21478806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine levels of the aqueous humour in central serous chorioretinopathy.
    Jung SH; Kim KA; Sohn SW; Yang SJ
    Clin Exp Optom; 2014 May; 97(3):264-9. PubMed ID: 24417755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab injection for central serous chorioretinopathy.
    Nowroozzadeh MH
    Retina; 2010 Sep; 30(8):1322-3; author reply 1323. PubMed ID: 20827148
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravitreal bevacizumab injection for central serous chorioretinopathy.
    Chhablani JK; Narayanan R
    Retina; 2010 Sep; 30(8):1323-24; author reply 1324. PubMed ID: 20661171
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravitreal bevacizumab injection for central serous chorioretinopathy.
    Lim SJ; Roh MI; Kwon OW
    Retina; 2010 Jan; 30(1):100-6. PubMed ID: 20010322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.
    Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
    Curr Eye Res; 2010 Feb; 35(2):91-8. PubMed ID: 20136418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema.
    Roh MI; Kim HS; Song JH; Lim JB; Kwon OW
    Ophthalmology; 2009 Jan; 116(1):80-6. PubMed ID: 19118699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
    Lim JW
    Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Aqueous Concentrations of Various Cytokines after Intravitreal Bevacizumab Injection for Chronic Central Serous Chorioretinopathy.
    Park J; Hwang SH; Nam DH; Lee DY
    Korean J Ophthalmol; 2023 Dec; 37(6):453-461. PubMed ID: 37899289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy.
    Lim JW; Kim MU
    Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):969-74. PubMed ID: 21140161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.
    Inoue M; Kadonosono K; Watanabe Y; Kobayashi S; Yamane S; Arakawa A
    Ophthalmologica; 2011; 225(1):37-40. PubMed ID: 20693820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.
    dell'Omo R; Cassetta M; dell'Omo E; di Salvatore A; Hughes JM; Aceto F; Porcellini A; Costagliola C
    Am J Ophthalmol; 2012 Jan; 153(1):155-61.e2. PubMed ID: 21861975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration.
    Muether PS; Hermann MM; Dröge K; Kirchhof B; Fauser S
    Am J Ophthalmol; 2013 Nov; 156(5):989-993.e2. PubMed ID: 23938122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor.
    Lee MY; Lee WK; Baek J; Kwon OW; Lee JH
    Am J Ophthalmol; 2013 Aug; 156(2):343-8. PubMed ID: 23664208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab.
    Zhou M; Chen S; Wang W; Huang W; Cheng B; Ding X; Zhang X
    Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):3874-9. PubMed ID: 23674760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathy.
    Okamoto M; Matsuura T; Ogata N
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):25-32. PubMed ID: 25559505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
    Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
    Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal ranibizumab for acute central serous chorioretinopathy.
    Kim M; Lee SC; Lee SJ
    Ophthalmologica; 2013; 229(3):152-7. PubMed ID: 23257663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment.
    Kaneda S; Miyazaki D; Sasaki S; Yakura K; Terasaka Y; Miyake K; Ikeda Y; Funakoshi T; Baba T; Yamasaki A; Inoue Y
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):2982-8. PubMed ID: 21273540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.